Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta‐Analysis
Brain and Behavior · 2026-05 · 16 (5)
DOI: 10.1002/brb3.71456 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Brain and Behavior, online erschienen am 28.04.2026. Verfasst von Kayode Agboola und 6 weiteren Autor:innen. Beteiligte Einrichtung: Facharztzentrum for Surgery and Orthopaedics, Essen, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Glioblastoma multiforme (GBM) poses significant challenges in oncology, with limited treatment options and poor prognosis. Despite advancements, recurrence remains common, emphasizing the need for effective therapeutic strategies. This meta‐analysis comprehensively evaluates the efficacy and safety of treatments like bevacizumab (BEV), temozolomide (TMZ), and lomustine (CCNU) for recurrent GBM (rGBM), aiming to identify optimal approaches and guide clinical decisions.
Methods
Following Preferred Reporting Standards for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, a systematic review was conducted, and randomized controlled trials assessing interventions for rGBM were included. The Cochrane risk‐of‐bias assessment was used to evaluate study quality. Primary outcomes included progression‐free survival (PFS) and overall survival (OS), whereas adverse events were assessed as secondary outcomes.
Results
Nine articles met the inclusion criteria, comprising a total of 1689 participants. BEV therapy outperformed pre‐BEV treatment across several parameters, including full resection (odds ratio [OR] = 14.50, 95% confidence intervals [CI]: 1.82–115.29, p = 0.01) and biopsy outcomes (OR = 18.67, 95% CI: 2.55–136.41, p = 0.04). BEV also demonstrated higher rates of MGMT promoter methylation at baseline (OR = 11.84, 95% CI: 1.87–74.77, p = 0.009), as well as associations with improved PFS (OR = 1.16, 95% CI: 0.10–2.22, p = 0.03) and OS (OR = 0.63, 95% CI: 0.01–1.26, p = 0.05) compared to pre‐BEV therapies. BEV monotherapy was associated with more favorable outcomes than combination therapies, with a pooled OR of 19.50 (95% CI: 2.69–141.35, p = 0.03) for corticosteroid use. Adverse event analysis revealed a lower incidence of CNS hemorrhage with standard therapy. TMZ outperformed the TMZ + CCNU combination in PFS (OR = 2.44, 95% CI: 1.23–4.83, p = 0.01), OS, and MGMT methylation (OR = 2.58, 95% CI: 1.40–4.78, p = 0.002).
Conclusion
BEV monotherapy emerges as a promising treatment for rGBM, with favorable outcomes in biopsy results, corticosteroid use, PFS, and OS. Future research is needed to confirm these findings and optimize BEV's clinical application, emphasizing tailored treatment strategies to improve patient prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Facharztzentrum for Surgery and Orthopaedics, Essen, Germany.
- Department of Neurosurgery, Romodanov Institute of Neurosurgery, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.
- Department of Neurosurgery, Medical Campus Oberfranken of FAU Erlangen, Bayreuth, Germany.
- Department of Neurosurgery, College of Medical Sciences, Bharatpur, Nepal.
- Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA.
Zitieren
APA
Agboola, K., Khafaji, F., Chaurasia, B., Qureshi, K., Yangi, K., Chavda, V., & Balak, N. (2026). Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta‐Analysis. Brain and Behavior, 16(5). https://doi.org/10.1002/brb3.71456
Vancouver
Agboola K, Khafaji F, Chaurasia B, Qureshi K, Yangi K, Chavda V, et al. Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta‐Analysis. Brain and Behavior. 2026;16(5). doi:10.1002/brb3.71456
BibTeX
@article{Agboola2026,
author = {Agboola, Kayode and Khafaji, Fatemeh and Chaurasia, Bipin and Qureshi, Kashif and Yangi, Kivanc and Chavda, Vishal and Balak, Naci},
title = {Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta‐Analysis},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {5},
doi = {10.1002/brb3.71456}
}
EUVIMED